Article

AAO testimony challenges 'passive verification'

Washington, DC-Testifying before the House Energy and Commerce Subcommittee on Commerce, Trade, and Consumer Protection, American Academy of Ophthalmology (AAO) member Oliver D. Schein, MD, MPH, MBA, called the practice of passive verification a flaw in the Fairness to Contact Lens Consumer Act (FCLCA).

Washington, DC-Testifying before the House Energy and Commerce Subcommittee on Commerce, Trade, and Consumer Protection, American Academy of Ophthalmology (AAO) member Oliver D. Schein, MD, MPH, MBA, called the practice of passive verification a flaw in the Fairness to Contact Lens Consumer Act (FCLCA).

"The academy believes [passive verification] lowers the bar for patient safety and opens the door for prescription verification failures that can ultimately result in patient harm," Dr. Schein said. He added that, in the interest of patient safety, contact lens prescriptions should be positively verified before being dispensed to the user.

Dr. Schein asserted that, since the FCLCA went into effect in August 2004, dispensers have logged numerous verification abuses that place contact lens sales ahead of patient safety, He cited a warning letter sent by the FTC in October 2005 to 1-800 Contacts Inc. resulting from frequent complaints about potential violations. Additionally, under the FCLCA, the FTC was required to study antitrust concerns in the sale of prescription contact lenses. The February 2005 study concluded: "It does not support the hypothesis that sellers are able to limit competition or harm consumers by charging higher prices for limited distribution or private label lenses."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.